Now FDA-cleared for CLL, Multiple Myeloma, and B-ALL
Monitor residual disease with clonoSEQ, FDA-cleared for MRD assessment in bone marrow from patients with multiple myeloma or B-ALL and blood or bone marrow from patients with CLL. clonoSEQ is covered by Medicare for patients with CLL, B-ALL or multiple myeloma. View the Technical Summary.
What is MRD?
Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.
LEARN MORE ABOUT MRD
clonoSEQ for Patients
With MRD testing, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment.
LEARN MORE ABOUT MRDclonoSEQ for Clinicians
clonoSEQ leverages the power of next-generation sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.
How clonoSEQ worksNews and Updates
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today received clearance from the U.S. Food and Drug Administration (FDA) for its clonoSEQ® Assay to detect and monitor minimal residual disease (MRD) in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).
May, 2020
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing.
View Press ReleaseApril, 2020
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19.
View Press ReleaseWhat We’re Sharing
Follow UsChronic Lymphocytic Leukemia (#CLL) is the newest FDA-cleared indication for clonoSEQ. https://t.co/l6tksZ6Suy clonoSEQ is FDA-cleared to assess MRD in patients with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/sE39cuZxFD pic.twitter.com/YCBVf2dhRm
— clonoSEQ (@clonoSEQ) August 6, 2020
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
Contact Us
Make an inquiry to learn more about our products.